Impact Factor
4.38
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
8.30
1,270 total citations
h5-index
53
h5 depth signal
Cited share
92.5%
148 of 160
Total citations
1,270
Citation footprint
Metric signal
8.04
External metric anchor
Self-citation
1.9%
24 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
389
United Kingdom
132
Italy
112
Germany
104
Australia
91
Citing Fields of Research
Psychiatry
270
Brain Neurological Disorders
158
Neurodegenerative Disorders
133
Neuromuscular Disorders
131
Neurosciences
111
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,937
Articles tracked across the journal lifetime
Indexed publication set
160
148 cited publications
Last 12 months
105
8.8 publications/month
Open access share
58.1%
61 OA publications in the last year
Leading citing country
United States
389 citing publications
Leading citing field
Psychiatry
270 citing publications
Latest tracked publication
10 October 2026
10 recent records available
Coverage & Indexing History
v15n1, Jan. 2001-
v15n1, Jan. 2001-
Active Coverage
Research Focus & Classification
Indexed Subjects
Psychiatry
Brain Neurological Disorders
Neuromuscular Disorders
Neurodegenerative Disorders
Anesthetic & Pain Medicine
Chronobiology
Substance Abuse
Broad Categories
Drug Therapy
Neurology
Pharmacology
Brain Neurological Disorders
Psychiatry
Neuromuscular Disorders
Chronobiology
Migraines & Headaches
Substance Abuse
MeSH Descriptors
Central Nervous System Diseases
Mental Disorders
Nervous System Diseases
Psychotropic Drugs
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1007/s40263-026-01341-5
Open DOI
A Phase 3, Multicenter, Randomized, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Tolerability of Serdexmethylphenidate/d-Methylphenidate Capsules in Chinese Children with Attention-Deficit/Hyperactivity Disorder
Background and Objective Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is a novel methylphenidate formulation designed to provide rapid onset and sustained symptom control in attention-deficit/hyperactivity disorder (ADHD). This p...
03
DOI 10.1007/s40263-026-01340-6
Open DOI
Cognitive Effects of Cenobamate as Compared to Perampanel: A Cross-Sectional Multicentre Study in 600 Patients
04
DOI 10.1007/s40263-026-01335-3
Open DOI
Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis
05
06
DOI 10.1007/s40263-026-01334-4
Open DOI
Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials
Background and Objectives This umbrella review of systematic reviews, meta-analyses, and completed phase 3 randomized controlled trials (RCTs) over the past 10 years covers approved pharmacological treatments for substance use disorders ...
07
08
DOI 10.1007/s40263-026-01336-2
Open DOI
Bistromathics in Epilepsy and the Relativity of Numbers
09
10
Bibliographical & Catalog Notes
Title from cover.
Also issued online.